US panel rejects epilepsy drug "black box" warning on suicidality
This article was originally published in Scrip
Executive Summary
Anti-epilepsy drugs are associated with an increased risk of suicidal thoughts and behaviour, the US FDA's outside advisors said on July 10th. However, they rejected the agency's proposal for a "black box" label warning, fearing it could unduly dissuade appropriate use and prescribing of the medicines.